CytoDyn Announces FDA Clearance of Its Phase II On
Post# of 154867
(Total Views: 504)
Posted On: 11/04/2024 8:31:34 AM
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
https://www.cytodyn.com/newsroom/press-releas...i-oncology
VANCOUVER, Washington, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it has received clearance from the FDA to commence its Phase II oncology trial. The study will evaluate the efficacy of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer (“CRC”).
This milestone reflects the continued positive development of the Company’s improved relationship with the FDA. Clearance for the Phase II oncology trial was achieved following productive feedback sessions with the FDA over the past few months and the submission of a final study protocol to the FDA in September 2024. As previously announced, the trial will be conducted in partnership with Syneos Health. A trial kickoff meeting has been set for late November 2024 and patient enrollment will begin in early 2025.
“We have appreciated the opportunity to work constructively with the FDA on the review and finalization of our CRC protocol,” said Dr. Jacob Lalezari CEO. “With the agency’s input and our partnership with Syneos Health, we are well positioned to advance our clinical evaluation of leronlimab for oncology and make real strides towards developing the treatment paths of tomorrow.”
So much for the quiet period...
https://www.cytodyn.com/newsroom/press-releas...i-oncology
VANCOUVER, Washington, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it has received clearance from the FDA to commence its Phase II oncology trial. The study will evaluate the efficacy of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer (“CRC”). This milestone reflects the continued positive development of the Company’s improved relationship with the FDA. Clearance for the Phase II oncology trial was achieved following productive feedback sessions with the FDA over the past few months and the submission of a final study protocol to the FDA in September 2024. As previously announced, the trial will be conducted in partnership with Syneos Health. A trial kickoff meeting has been set for late November 2024 and patient enrollment will begin in early 2025.
“We have appreciated the opportunity to work constructively with the FDA on the review and finalization of our CRC protocol,” said Dr. Jacob Lalezari CEO. “With the agency’s input and our partnership with Syneos Health, we are well positioned to advance our clinical evaluation of leronlimab for oncology and make real strides towards developing the treatment paths of tomorrow.”
So much for the quiet period...
(9)
(0)CytoDyn Inc (CYDY) Stock Research Links
My comments are just my opinions and should NOT be taken as investment advice.